Mode of action of ticlopidine in inhibition of platelet aggregation in the rat
- PMID: 224522
Mode of action of ticlopidine in inhibition of platelet aggregation in the rat
Abstract
Ticlopidine, when orally administered to rats, resulted in activation of basal and prostaglandin E1 (PGE1)-stimulated adenylate cylase activity through increase in affinity of the cyclase in platelet membrane to PGE1, although it failed to affect adenosine- or sodium fluoride-stimulated activity of the enzyme. In washed platelets, Ticlopidine also activated basal and PGE1-stimulated activity of the cyclase and prevented reduction in the cyclase activity caused by low concentrations of PGE2. Furthermore, Ticlopidine inhibited malondialdehyde formation in platelets induced by thrombin but failed to inhibit that caused by exogenous arachidonic acid. Adenosine 3',5'-cyclic monophosphate (c-AMP): phosphodiesterase activity of platelet lysate was not significantly affected by Ticlopidine treatment. These findings indicate that Ticlopidine inhibits platelet aggregation and prostaglandin synthesis from endogenous substrate through activating basal and PGE1-stimulated activity of the cyclase, preventing PGE2-induced depression of the cyclase activity and thus increasing platelet c-AMP level.
Similar articles
-
Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP.Mol Pharmacol. 1990 May;37(5):671-81. Mol Pharmacol. 1990. PMID: 2160060
-
Effect of adenyl-cyclase activators, phosphodiesterase inhibitors and pyridoxal-5-phosphate on platelet aggregation and adenosine-3'-5'-cyclic monophosphate accumulation.Thromb Haemost. 1984 Oct 31;52(2):205-9. Thromb Haemost. 1984. PMID: 6098048
-
Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits.Thromb Haemost. 1991 Feb 12;65(2):186-90. Thromb Haemost. 1991. PMID: 2053105
-
[Mechanism of platelet aggregation inhibition].Rinsho Byori. 1979;Suppl 40:169-80. Rinsho Byori. 1979. PMID: 233105 Review. Japanese. No abstract available.
-
[Cyclic nucleotides and blood platelet functions].Nihon Rinsho. 1978 Dec 10;36(12):3813-8. Nihon Rinsho. 1978. PMID: 34743 Review. Japanese. No abstract available.
Cited by
-
Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.Agents Actions. 1984 Jan;14(1):109-12. doi: 10.1007/BF01966842. Agents Actions. 1984. PMID: 6702507 No abstract available.
-
Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication.J Clin Pathol. 1982 Jul;35(7):740-3. doi: 10.1136/jcp.35.7.740. J Clin Pathol. 1982. PMID: 7047575 Free PMC article. Clinical Trial.
-
Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states.Drugs. 1987 Aug;34(2):222-62. doi: 10.2165/00003495-198734020-00003. Drugs. 1987. PMID: 3304967 Review.
-
Functionally thrombasthenic state in normal platelets following the administration of ticlopidine.J Clin Invest. 1985 Feb;75(2):328-38. doi: 10.1172/JCI111705. J Clin Invest. 1985. PMID: 3156146 Free PMC article.
-
Analysis of antiplatelet effect of ticlopidine in humans: modeling based on irreversible inhibition of platelet precursors in bone marrow.J Pharmacokinet Biopharm. 1999 Jun;27(3):283-96. doi: 10.1023/a:1020995013200. J Pharmacokinet Biopharm. 1999. PMID: 10728490